Urapidil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Urapidil
Accession Number
DB12661
Type
Small Molecule
Groups
Investigational
Description

Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
A78GF17HJS
CAS number
34661-75-1
Weight
Average: 387.484
Monoisotopic: 387.227039814
Chemical Formula
C20H29N5O3
InChI Key
ICMGLRUYEQNHPF-UHFFFAOYSA-N
InChI
InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
IUPAC Name
6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
COC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineUrapidil may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Urapidil.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
AcemetacinThe therapeutic efficacy of Urapidil can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineUrapidil may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AdrafinilUrapidil may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineThe risk or severity of hypotension can be increased when Urapidil is combined with Agmatine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Urapidil.Approved, Investigational
AliskirenUrapidil may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Withdrawn
AmbrisentanUrapidil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronUrapidil may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineUrapidil may increase the hypotensive activities of Amifostine.Approved, Investigational
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
AmitrazUrapidil may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineUrapidil may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineUrapidil may increase the hypotensive activities of Amlodipine.Approved
AmoxapineUrapidil may increase the antihypertensive activities of Amoxapine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Urapidil.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Urapidil is combined with Amrinone.Approved
AnisodamineUrapidil may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineUrapidil may decrease the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineUrapidil may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Urapidil is combined with Aranidipine.Approved, Investigational
ArbutamineUrapidil may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolUrapidil may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleUrapidil may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
AsenapineUrapidil may increase the antihypertensive activities of Asenapine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Urapidil.Approved
AvanafilAvanafil may increase the hypotensive activities of Urapidil.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Urapidil is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Urapidil is combined with Azimilide.Investigational
BambuterolUrapidil may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarnidipineUrapidil may increase the antihypertensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Urapidil.Experimental
BenazeprilUrapidil may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Urapidil is combined with Bencyclane.Experimental
BendroflumethiazideUrapidil may increase the hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe risk or severity of hypotension can be increased when Urapidil is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Urapidil.Withdrawn
BenzphetamineUrapidil may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
BepridilUrapidil may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Urapidil.Approved
BevantololUrapidil may increase the antihypertensive activities of Bevantolol.Approved
BietaserpineUrapidil may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostUrapidil may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Urapidil is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Urapidil.Approved
BitolterolUrapidil may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Urapidil.Approved
BosentanBosentan may increase the hypotensive activities of Urapidil.Approved, Investigational
BQ-123Urapidil may increase the hypotensive activities of BQ-123.Investigational
BretyliumUrapidil may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleUrapidil may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Urapidil.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Urapidil.Experimental
BromocriptineUrapidil may decrease the vasoconstricting activities of Bromocriptine.Approved, Investigational
BucindololUrapidil may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Urapidil.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Urapidil.Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Urapidil.Approved
CadralazineUrapidil may increase the hypotensive activities of Cadralazine.Experimental
CafedrineUrapidil may increase the hypotensive activities of Cafedrine.Investigational
CandesartanUrapidil may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilUrapidil may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilUrapidil may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilUrapidil may increase the hypotensive activities of Captopril.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Urapidil is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Urapidil is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Urapidil.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Urapidil.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Urapidil.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
ChlorothiazideUrapidil may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineUrapidil may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneUrapidil may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineUrapidil may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilUrapidil may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Urapidil is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Urapidil is combined with Cinnarizine.Approved, Investigational
CirazolineUrapidil may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolUrapidil may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Urapidil is combined with Clevidipine.Approved, Investigational
ClonidineUrapidil may decrease the vasoconstricting activities of Clonidine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Urapidil.Experimental
ClozapineUrapidil may increase the antihypertensive activities of Clozapine.Approved
CryptenamineUrapidil may increase the hypotensive activities of Cryptenamine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Urapidil is combined with Cyclandelate.Approved
CyclopenthiazideUrapidil may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideUrapidil may increase the hypotensive activities of Cyclothiazide.Approved
DapiprazoleUrapidil may increase the antihypertensive activities of Dapiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Urapidil.Investigational
DarodipineThe risk or severity of hypotension can be increased when Urapidil is combined with Darodipine.Experimental
DebrisoquinDebrisoquin may increase the hypotensive activities of Urapidil.Approved, Investigational
DelaprilUrapidil may increase the hypotensive activities of Delapril.Investigational
DeserpidineUrapidil may increase the hypotensive activities of Deserpidine.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
DetomidineUrapidil may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineUrapidil may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineUrapidil may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Urapidil.Approved
DiethylnorspermineUrapidil may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Urapidil.Approved, Investigational
DihydroergotamineUrapidil may decrease the vasoconstricting activities of Dihydroergotamine.Approved, Investigational
DiltiazemUrapidil may increase the hypotensive activities of Diltiazem.Approved, Investigational
DipivefrinUrapidil may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Urapidil.Approved
DL-MethylephedrineUrapidil may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineUrapidil may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineUrapidil may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DorzolamideUrapidil may increase the hypotensive activities of Dorzolamide.Approved
DotarizineThe risk or severity of hypotension can be increased when Urapidil is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Urapidil.Approved
DoxepinUrapidil may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineUrapidil may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DronedaroneUrapidil may increase the antihypertensive activities of Dronedarone.Approved
DroperidolUrapidil may increase the antihypertensive activities of Droperidol.Approved, Vet Approved
DroxidopaUrapidil may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
EfonidipineUrapidil may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilUrapidil may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatUrapidil may increase the hypotensive activities of Enalaprilat.Approved
EndralazineUrapidil may increase the hypotensive activities of Endralazine.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Urapidil.Experimental
EperisoneThe risk or severity of hypotension can be increased when Urapidil is combined with Eperisone.Approved, Investigational
EphedraUrapidil may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineUrapidil may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineUrapidil may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineUrapidil may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolUrapidil may increase the hypotensive activities of Epoprostenol.Approved
EprosartanUrapidil may increase the hypotensive activities of Eprosartan.Approved
ErgonovineUrapidil may decrease the vasoconstricting activities of Ergonovine.Approved
ErgotamineUrapidil may decrease the vasoconstricting activities of Ergotamine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Urapidil.Experimental
EscitalopramUrapidil may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Urapidil.Approved
EtafedrineUrapidil may decrease the vasoconstricting activities of Etafedrine.Approved
EthosuximideThe risk or severity of hypotension can be increased when Urapidil is combined with Ethosuximide.Approved
EtilefrineUrapidil may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidateUrapidil may decrease the vasoconstricting activities of Etomidate.Approved
FelodipineUrapidil may increase the hypotensive activities of Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Urapidil is combined with Fendiline.Withdrawn
FenoldopamUrapidil may increase the hypotensive activities of Fenoldopam.Approved
FenoterolUrapidil may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Ferulic acidUrapidil may increase the hypotensive activities of Ferulic acid.Experimental
Fish oilThe risk or severity of hypotension can be increased when Urapidil is combined with Fish oil.Approved, Nutraceutical
FlunarizineThe risk or severity of hypotension can be increased when Urapidil is combined with Flunarizine.Approved
FlupentixolUrapidil may increase the antihypertensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Urapidil is combined with Fluspirilene.Approved, Investigational
FormoterolUrapidil may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilUrapidil may increase the hypotensive activities of Fosinopril.Approved
FostamatinibFostamatinib may increase the hypotensive activities of Urapidil.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Urapidil.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of hypotension can be increased when Urapidil is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Urapidil is combined with Gallopamil.Investigational
GuanabenzUrapidil may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanadrelUrapidil may increase the hypotensive activities of Guanadrel.Approved
GuanazodineUrapidil may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineUrapidil may increase the hypotensive activities of Guanethidine.Approved
GuanfacineUrapidil may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
GuanoclorUrapidil may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzUrapidil may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanUrapidil may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Urapidil.Experimental
HexamethoniumUrapidil may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineUrapidil may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineUrapidil may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Urapidil.Experimental
HydralazineHydralazine may increase the hypotensive activities of Urapidil.Approved
HydrochlorothiazideUrapidil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideUrapidil may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IloperidoneUrapidil may increase the antihypertensive activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Urapidil.Approved, Investigational
ImidaprilUrapidil may increase the hypotensive activities of Imidapril.Investigational
ImipramineUrapidil may increase the antihypertensive activities of Imipramine.Approved
IndacaterolUrapidil may decrease the vasoconstricting activities of Indacaterol.Approved
IndapamideUrapidil may increase the hypotensive activities of Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Urapidil.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Urapidil.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Urapidil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Urapidil.Withdrawn
IrbesartanUrapidil may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Urapidil.Approved
IsoetarineUrapidil may decrease the vasoconstricting activities of Isoetarine.Approved
IsomethepteneUrapidil may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineUrapidil may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineUrapidil may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineUrapidil may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Urapidil.Investigational
LabetalolLabetalol may increase the antihypertensive activities of Urapidil.Approved
LacidipineUrapidil may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Urapidil is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
LatanoprostUrapidil may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineUrapidil may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Urapidil is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
LevosalbutamolUrapidil may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Urapidil is combined with Lidoflazine.Experimental
LinsidomineUrapidil may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineUrapidil may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilUrapidil may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineUrapidil may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Urapidil is combined with Loperamide.Approved
LosartanUrapidil may increase the hypotensive activities of Losartan.Approved
MacitentanUrapidil may increase the hypotensive activities of Macitentan.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Urapidil is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineUrapidil may increase the hypotensive activities of Manidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Urapidil.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Urapidil.Approved, Investigational
MedetomidineUrapidil may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MentholThe risk or severity of hypotension can be increased when Urapidil is combined with Menthol.Approved
MephentermineUrapidil may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Urapidil.Experimental
MetaraminolUrapidil may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethamphetamineUrapidil may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethoserpidineUrapidil may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineUrapidil may increase the antihypertensive activities of Methotrimeprazine.Approved, Investigational
MethoxamineUrapidil may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineUrapidil may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Urapidil is combined with Methsuximide.Approved
MethyldopaUrapidil may decrease the vasoconstricting activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Urapidil.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Urapidil.Approved, Investigational
MetipranololUrapidil may increase the hypotensive activities of Metipranolol.Approved
MetolazoneUrapidil may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
MetyrosineUrapidil may increase the hypotensive activities of Metyrosine.Approved
MibefradilUrapidil may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineUrapidil may decrease the vasoconstricting activities of Midodrine.Approved
MinaprineMinaprine may increase the hypotensive activities of Urapidil.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Urapidil.Approved, Investigational
MirabegronUrapidil may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Urapidil.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Urapidil.Approved, Investigational
MoexiprilUrapidil may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Urapidil.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Urapidil.Approved, Investigational
MuzolimineUrapidil may increase the hypotensive activities of Muzolimine.Experimental
NadololNadolol may increase the orthostatic hypotensive activities of Urapidil.Approved
NaftopidilUrapidil may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineUrapidil may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
NefazodoneUrapidil may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypotensive activities of Urapidil.Withdrawn
NicardipineUrapidil may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineUrapidil may increase the antihypertensive activities of Nicergoline.Approved, Investigational
NicorandilUrapidil may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Urapidil is combined with Nifedipine.Approved
NiguldipineUrapidil may increase the antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Urapidil is combined with Niludipine.Experimental
NilvadipineUrapidil may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Urapidil is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineUrapidil may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineUrapidil may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineUrapidil may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Urapidil.Approved, Investigational
NorepinephrineUrapidil may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineUrapidil may decrease the vasoconstricting activities of Norfenefrine.Experimental
NortriptylineUrapidil may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinUrapidil may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabUrapidil may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Urapidil.Withdrawn
OctopamineUrapidil may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineUrapidil may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlmesartanUrapidil may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolUrapidil may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatUrapidil may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineUrapidil may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumThe risk or severity of hypotension can be increased when Urapidil is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Urapidil.Approved
OxyfedrineUrapidil may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineUrapidil may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
PaliperidoneUrapidil may increase the antihypertensive activities of Paliperidone.Approved
PargylinePargyline may increase the hypotensive activities of Urapidil.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
PentoliniumUrapidil may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Urapidil.Approved, Investigational
PergolideUrapidil may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilUrapidil may increase the hypotensive activities of Perindopril.Approved
PhendimetrazineUrapidil may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypotensive activities of Urapidil.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Urapidil.Withdrawn
PhenoxybenzamineUrapidil may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Urapidil.Withdrawn
PhentolamineUrapidil may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineUrapidil may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineUrapidil may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinacidilPinacidil may increase the hypotensive activities of Urapidil.Approved
PinaveriumThe risk or severity of hypotension can be increased when Urapidil is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
PirbuterolUrapidil may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Urapidil.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Urapidil.Withdrawn
PizotifenUrapidil may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Urapidil.Experimental
PolythiazideUrapidil may increase the hypotensive activities of Polythiazide.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Urapidil.Approved
PrazosinPrazosin may increase the antihypertensive activities of Urapidil.Approved
PrenalterolUrapidil may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Urapidil is combined with Prenylamine.Withdrawn
ProcaineProcaine may increase the hypotensive activities of Urapidil.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Urapidil.Approved, Investigational
ProcaterolUrapidil may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazineUrapidil may increase the antihypertensive activities of Promazine.Approved, Vet Approved
PropafenonePropafenone may increase the orthostatic hypotensive activities of Urapidil.Approved
PropericiazineUrapidil may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazineUrapidil may increase the antihypertensive activities of Propiomazine.Approved
PropiverineUrapidil may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropranololPropranolol may increase the orthostatic hypotensive activities of Urapidil.Approved, Investigational
ProtokylolUrapidil may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
PseudoephedrineUrapidil may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineUrapidil may increase the antihypertensive activities of Quetiapine.Approved
QuinaprilUrapidil may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineUrapidil may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Urapidil.Approved
RacepinephrineUrapidil may increase the antihypertensive activities of Racepinephrine.Approved
RactopamineUrapidil may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilUrapidil may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Urapidil.Approved
RemikirenUrapidil may increase the hypotensive activities of Remikiren.Approved
ReproterolUrapidil may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineUrapidil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Urapidil.Approved, Investigational
RilmenidineUrapidil may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolUrapidil may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatUrapidil may increase the hypotensive activities of Riociguat.Approved
RisperidoneUrapidil may increase the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronUrapidil may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineUrapidil may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RituximabUrapidil may increase the hypotensive activities of Rituximab.Approved
RomifidineUrapidil may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleUrapidil may decrease the vasoconstricting activities of Ropinirole.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Urapidil.Withdrawn
SalbutamolUrapidil may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolUrapidil may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanUrapidil may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Urapidil.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Urapidil is combined with Seletracetam.Investigational
SelexipagUrapidil may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the hypotensive activities of Urapidil.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Urapidil.Approved
SitaxentanUrapidil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolabegronUrapidil may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Urapidil.Approved
SpiraprilUrapidil may increase the hypotensive activities of Spirapril.Approved
SynephrineUrapidil may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Urapidil.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Urapidil.Approved, Investigational
TelmisartanUrapidil may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilUrapidil may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Urapidil.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Urapidil.Approved
TerlipressinUrapidil may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineThe risk or severity of hypotension can be increased when Urapidil is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Urapidil.Experimental
TetrahydropalmatineUrapidil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineUrapidil may decrease the vasoconstricting activities of Tetryzoline.Approved
TheodrenalineUrapidil may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the hypotensive activities of Urapidil.Approved
ThioproperazineUrapidil may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineUrapidil may increase the antihypertensive activities of Thioridazine.Approved, Withdrawn
TiboloneUrapidil may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenUrapidil may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Urapidil.Approved
TizanidineUrapidil may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineUrapidil may increase the antihypertensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Urapidil is combined with Tolfenamic Acid.Approved, Investigational
TolonidineUrapidil may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Urapidil.Approved
TorasemideUrapidil may increase the hypotensive activities of Torasemide.Approved
TrandolaprilUrapidil may increase the hypotensive activities of Trandolapril.Approved
TranilastThe risk or severity of hypotension can be increased when Urapidil is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Urapidil.Approved, Investigational
TravoprostUrapidil may increase the hypotensive activities of Travoprost.Approved
TrazodoneUrapidil may increase the antihypertensive activities of Trazodone.Approved, Investigational
TreprostinilUrapidil may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretoquinolUrapidil may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrichlormethiazideUrapidil may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineUrapidil may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Urapidil.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Urapidil is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Urapidil is combined with Trimethadione.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Urapidil.Approved, Investigational
TrimipramineUrapidil may increase the antihypertensive activities of Trimipramine.Approved
TulobuterolUrapidil may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Urapidil.Approved, Investigational
UnoprostoneUrapidil may increase the hypotensive activities of Unoprostone.Approved, Investigational
ValsartanUrapidil may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Urapidil.Approved
VerapamilUrapidil may increase the antihypertensive activities of Verapamil.Approved
VilanterolUrapidil may decrease the vasoconstricting activities of Vilanterol.Approved
VincamineUrapidil may increase the hypotensive activities of Vincamine.Experimental
VinpocetineUrapidil may increase the hypotensive activities of Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Urapidil is combined with WIN 55212-2.Experimental
XamoterolUrapidil may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamideUrapidil may increase the hypotensive activities of Xipamide.Experimental
XylazineUrapidil may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineUrapidil may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Urapidil.Approved, Investigational, Vet Approved
ZiconotideThe risk or severity of hypotension can be increased when Urapidil is combined with Ziconotide.Approved
ZiprasidoneUrapidil may increase the antihypertensive activities of Ziprasidone.Approved
ZofenoprilUrapidil may increase the hypotensive activities of Zofenopril.Experimental
ZonisamideThe risk or severity of hypotension can be increased when Urapidil is combined with Zonisamide.Approved, Investigational
ZuclopenthixolUrapidil may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5639
PubChem Substance
347828865
ChemSpider
5437
ChEBI
32278
ChEMBL
CHEMBL279229
Wikipedia
Urapidil
ATC Codes
C02CA06 — Urapidil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentAortic Dissection Type B / High Blood Pressure (Hypertension)1
3RecruitingTreatmentHigh Blood Pressure (Hypertension) / Preeclampsia1
3Unknown StatusTreatmentHypertension During Pre-Eclampsia1
4RecruitingTreatmentNontraumatic Intracerebral Hemorrhage, Multiple Localized1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableRecruitingDiagnosticGeneral Surgery1
Not AvailableRecruitingTreatmentAging / Anaesthesia therapy / Blood Loss,Surgical / Blood Pressures / General Surgery / Postoperative Delirium1
Not AvailableRecruitingTreatmentScheduled Laparoscopic Surgery1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.541 mg/mLALOGPS
logP1.69ALOGPS
logP1.18ChemAxon
logS-2.9ALOGPS
pKa (Strongest Basic)8.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.36 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity119.37 m3·mol-1ChemAxon
Polarizability43.07 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0439000000-1f066af9035f53bb2d89
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0900000000-2ccc838e7c2c252cb8ad

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Aminophenyl ethers / Methoxyanilines / Anisoles / Dialkylarylamines / Methoxybenzenes / Phenoxy compounds / N-alkylpiperazines / Aminopyrimidines and derivatives / Alkyl aryl ethers
show 12 more
Substituents
Phenylpiperazine / N-arylpiperazine / Aminophenyl ether / Methoxyaniline / Tertiary aliphatic/aromatic amine / Phenoxy compound / Anisole / Dialkylarylamine / Aniline or substituted anilines / Phenol ether
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:31 / Updated on July 02, 2018 19:39